Arcutis Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
06/08/2025 22:02
Arcutis Biotherapeutics Inc ARQT.OQ reported a quarterly adjusted loss of 13 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -42 cents. The mean expectation of eight analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -20 cents to -11 cents per share. Revenue rose 164.1% to $81.50 million from a year ago; analysts expected $73.69 million. Arcutis Biotherapeutics Inc's reported EPS for the quarter was a loss of 13 cents. The company reported a quarterly loss of $15.54 million. Arcutis Biotherapeutics Inc shares had risen by 9.3% this quarter and gained 10.0% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 7.5% in the last three months. In the last 30 days, there have been no negative revisions of earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $20.00, about 23.4% above its last closing price of $15.33 This summary was machine generated from LSEG data August 6 at 09:02 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.16 | -0.13 | Beat |
| Mar. 31 2025 | -0.21 | -0.20 | Beat |
| Dec. 31 2024 | -0.25 | -0.09 | Beat |
| Sep. 30 2024 | -0.42 | -0.33 | Beat |
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf